Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: Mol Cancer Res. 2020 Jun 30;19(1):3–13. doi: 10.1158/1541-7786.MCR-20-0404

Fig. 4.

Fig. 4.

Inhibition of JMJD1 proteins by oncometabolites. Shown are the tricarboxylic acid cycle and the production of the oncometabolites succinate, fumarate and 2-hydroxyglutarate that may inhibit catalytic activity of JMJD1 proteins. Loss-of-function mutations in succinate dehydrogenase and fumarate hydratase lead to the accumulation of fumarate and succinate, while neomorphic gain-of-function mutations in isocitrate dehydrogenase cause the reduction of 2-oxoglutarate into 2-hydroxyglutarate.